Detalhe da pesquisa
1.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood
; 143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
2.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
3.
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality.
J Transl Med
; 21(1): 515, 2023 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37518011
4.
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Mol Cell
; 34(4): 461-72, 2009 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-19481526
5.
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).
Blood Cancer Discov
; 5(1): 21-33, 2024 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983485
6.
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Bone Marrow Transplant
; 59(3): 366-372, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177222
7.
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
Nat Med
; 30(2): 507-518, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233586
8.
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
J Clin Oncol
; 41(3): 555-567, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658525
9.
Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs.
Mutagenesis
; 27(1): 93-101, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21852270
10.
Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.
Blood
; 113(11): 2478-87, 2009 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-19147787
11.
Distinct contributions of microtubule subtypes to cell membrane shape and stability.
Nanomedicine
; 3(1): 43-52, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17379168
12.
The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
Mol Cancer Res
; 13(3): 502-9, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25368431
13.
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
Cancer Discov
; 4(4): 452-65, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24444711
14.
IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex.
Cell Rep
; 3(3): 724-33, 2013 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23453969
15.
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers.
Cancer Discov
; 3(9): 1044-57, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23764425
16.
IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation.
Mol Cell Biol
; 32(23): 4756-68, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23007157
17.
Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
Cell
; 129(6): 1065-79, 2007 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17574021
18.
Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.
Blood
; 108(6): 1991-8, 2006 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16728701
19.
TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin.
Blood
; 101(12): 5007-9, 2003 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12576313
20.
Transdifferentiation and nuclear reprogramming in hematopoietic development and neoplasia.
Immunol Rev
; 187: 22-39, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12366680